Medopad, the UK startup that has been working with Tencent to develop AI-based methods for building and tracking “digital” biomarkers — measurable indicators of the progression of illnesses and diseases that are picked up not with blood samples or in-doctor visits but using apps and wearables, has announced another round of funding to expand the scope of its developments.
It has picked up $25 million led by pharmaceuticals giant Bayer, which will be working together with Medopad to build digital biomarkers and therapeutics related to heart health.
While Medopad also tracks biomarkers, it’s taking a very different, non-invasive route to building its solutions.
The company constructs its algorithms and tracking working with pharmaceutical and tech partners to build the solution end-to-end, leaning on advances in software and hardware to fulfil ideas that have been unattainable goals for a long time.
In recent times, however, with the advent of advanced computer vision and far better sensors on devices, a new category of digital biomarkers, as Vahdat calls them, are being created — for example, by tracking how a person is walking — her/his gait and other metrics — to provide similar guidance to a clinician on the patient’s progress.
Vahdat said that all patient data is only collected with consent, and if any data from Medopad is passed to its partners, it’s anonymised.